NASDAQ : SRZN
Surrozen, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 29.46 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 515.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 508.06M |
| Enterprise Value | 412.34M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 17.50M |
| Shares Outstanding | 17.50M |
| Shares Change (YoY) | +115.86% |
| Shares Change (QoQ) | +111.32% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 45.30% |
| Float | 9.91M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.14 |
| Forward PS | 191.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 35.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.14 |
| Quick Ratio | 11.88 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.39% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -41.61% |
| Weighted Average Cost of Capital (WACC) | 6.72% |
| Revenue Per Employee | $261,614 |
| Profits Per Employee | -$7.38M |
| Employee Count | 44 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +113.69% |
| 50-Day Moving Average | 24.31 |
| 200-Day Moving Average | 25.10 |
| Relative Strength Index (RSI) | 58.04 |
| Average Volume (20 Days) | 527,276 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.13M |
| Short Previous Month | 2.19M |
| Short % of Shares Out | 17.90% |
| Short % of Float | 31.59% |
| Short Ratio (days to cover) | 2.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 11.51M |
| Gross Profit | -23.07M |
| Operating Income | -44.35M |
| Pretax Income | -332.13M |
| Net Income | -324.56M |
| EBITDA | -44.13M |
| EBIT | -44.35M |
| Loss Per Share | -$32.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 102.04M |
| Total Debt | 6.32M |
| Net Cash | 95.72M |
| Net Cash Per Share | $5.47 |
| Equity (Book Value) | -218.67M |
| Book Value Per Share | -18.60 |
| Working Capital | 100.39M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -34.76M |
| Capital Expenditures | -222,000 |
| Depreciation & Amortization | 222,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -34.98M |
| FCF Per Share | -$2.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | -200.38% |
| Operating Margin | -385.28% |
| Pretax Margin | -2,885.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -115.86% |
| Shareholder Yield | -115.86% |
| Earnings Yield | -110.84% |
| FCF Yield | -6.89% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $47.50 |
| Price Target Difference | 63.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -37.00% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -7.1 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |